Invivyd Upsizes COVID-19 Trial, Advances Novel Measles Candidate

Event summary

  • Invivyd is expanding its DECLARATION Phase 3 COVID-19 trial by ~500 subjects, shifting the expected top-line results to Q3 2026.
  • The trial upsizing is based on accumulated data showing sufficient statistical power to support the high end of anticipated efficacy, with only 50% of the study completed.
  • Invivyd has initiated IND-enabling work for VMS063, a novel measles monoclonal antibody candidate, targeting IND readiness by late 2026.
  • The company is facing a resurgence of measles in the U.S., with infection rates exceeding 2025 levels and a significant immunity gap affecting millions.

The big picture

Invivyd's strategic pivot towards monoclonal antibody therapies for infectious diseases, particularly with the advancement of VMS063, represents a bet against the continued dominance of mRNA vaccines. The company’s focus on addressing unmet needs in measles treatment and prevention, coupled with the expanded COVID-19 trial, positions it to capitalize on a resurgence of infectious disease threats and potentially disrupt the current vaccine landscape. The measles market, while niche, represents a significant opportunity for a targeted therapeutic intervention.

What we're watching

Clinical Execution
The success of the expanded DECLARATION trial hinges on recruitment rates and continued event accumulation; delays could further push back results and impact investor confidence.
Regulatory Pathway
The FDA’s acceptance of Invivyd’s Pediatric Study Plan for VYD2311 will be a key indicator of the antibody’s overall regulatory trajectory and potential for pediatric market access.
Market Adoption
The commercial viability of VMS063 will depend on its ability to address the unmet need for measles treatment and prophylaxis, particularly among vulnerable populations hesitant to or unable to receive vaccination.

Related topics

Public Health